HBOT Market Poised for Strong Growth: Monoplace Chambers Lead the Way
Recent market data show that the global hyperbaric oxygen therapy (HBOT) market is entering a high-growth phase — expanding from roughly US $3.98 billion in 2025 to more than US $6.7 billion by 2034 (Precedence Research).
Monoplace chambers — compact systems designed for a single patient — are driving the largest share of this expansion as hospitals and physician offices increasingly adopt outpatient-friendly HBOT solutions (Future Market Insights).
Why This Matters for RxAir360
- Strengthens the business case for RxAir360's vertical monoplace chamber, purpose-built for office integration
- Highlights growing demand and reimbursement potential across multiple specialties
- Supports the investor narrative of a large and expanding total addressable market
"The HBOT industry is growing quickly. Once we receive FDA clearance to sell and market the RxAir360, we will be in a unique position to offer a safer, smarter, and more accessible chamber for the physicians who are instrumental in patient recovery."
— Diallo M. Watts Sr., Founder & CEO of RxAir360 Inc.
Key Takeaway: With the HBOT market set to nearly double in size this decade, RxAir360's physician-office chamber is at the forefront of next-generation oxygen therapy.